Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Celyad Oncology SA

Company price
0.28 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
100
Market Cap
16.60M
P/E
17.50

Momentum Score

…

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.28
Low
0.32
High
52 Week Price Range
0.15
Low
0.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Celyad Oncology SA is a clinical-stage biopharmaceutical company developing cell-based immunotherapies, principally CAR-T approaches, for oncology indications. Its long-term growth drivers include progress in clinical trials, potential regulatory approvals, and advancement of scalable manufacturing and platform technologies that may support commercialization, and investors may find the company attractive for upside linked to successful clinical outcomes and platform validation.
Material investment risks include clinical and regulatory setbacks, lack of commercial revenue and recurring financing needs that could dilute shareholders, intense competition in cell therapy, and significant manufacturing and operational complexity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.28
Dividend Yield
-
Revenue TTM
0.02M
Revenue Per Share
-
Gross Profit TTM
0.01M
Debt / Equity
-1.09
ROE
56.33%
Net Debt
-1.71M
ROCE
-289.60%
Diluted EPS TTM
0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.66M -5.96M -8.51M -40.87M -26.50M
Net income 0.83M -5.82M -8.45M -40.94M -26.51M
Selling general administrative 1.70M - 5.71M 10.34M 9.66M
Selling and marketing expenses - - 0.21M 0.24M 0.43M
Gross profit 1.93M 0.92M 0.03M -1.44M -1.52M
Reconciled depreciation 0.17M - - 1.44M 1.52M
Ebit -7.18M -5.84M -8.56M -41.13M -26.93M
Ebitda -7.01M -5.39M -7.76M -39.70M -25.41M
Depreciation and amortization 0.17M 0.45M 0.79M 1.44M 1.52M
Operating income -7.18M -6.26M -8.46M -40.86M -26.39M
Other operating expenses 7.20M 6.45M 8.56M 20.26M 26.91M
Interest expense 0.06M 0.12M 0.08M 0.20M 0.26M
Tax provision 0.00M - - 0.07M 0.01M
Interest income 0.01M - - 0.01M 0.03M
Net interest income -0.05M - - -0.18M -0.12M
Income tax expense -1.49M -0.14M -0.19M 0.07M 0.01M
Total revenue 0.02M 0.19M 0.10M 0.00M 0.00M
Total operating expenses 9.11M 7.18M 8.49M 20.26M 26.91M
Cost of revenue -1.91M -0.73M 0.07M 1.44M 1.52M
Total other income expense net 6.53M 0.30M -0.05M -0.01M -0.11M
Net income from continuing ops 0.83M - - -40.94M -26.51M
Net income applicable to common shares - - - -40.94M -26.51M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4.30M 9.93M 16.28M 19.72M 79.94M
Intangible assets 0.02M 0.41M 0.05M 0.86M 35.28M
Other current assets 1.00M 0.99M 3.74M 0.45M 0.25M
Total liab 1.86M 26.05M 9.98M 15.40M 36.30M
Total stockholder equity 2.44M -16.12M 6.30M 4.32M 43.64M
Deferred long term liab - - - 0.41M 0.47M
Other current liab 0.66M 0.69M 1.53M 4.21M 4.86M
Common stock 9.22M 8.22M 32.95M 78.58M 78.58M
Capital stock 9.22M - - 78.58M 78.58M
Retained earnings -363.37M -364.20M -358.37M -349.95M -309.00M
Other liab - - - 4.86M 20.75M
Good will 0.00M - 0.34M 0.00M 0.88M
Other assets - - - 4.13M 6.71M
Cash 1.71M 4.20M 7.00M 12.45M 30.02M
Total current liabilities 1.82M 2.85M 2.93M 10.43M 13.83M
Current deferred revenue 0.65M 0.79M 0.51M 1.33M 1.46M
Net debt -1.71M 13.34M -5.95M -12.19M -27.39M
Short term debt - 0.14M 0.16M 0.14M 0.90M
Short long term debt total - 17.54M 1.06M 0.26M 2.63M
Other stockholder equity - 0.00M 0.00M 6.32M 6.32M
Property plant equipment - - - 0.31M 3.25M
Total current assets 3.50M 6.51M 11.12M 14.82M 34.29M
Net tangible assets - - - 3.86M 7.95M
Short term investments - - - 0.00M 0.00M
Net receivables 0.79M 0.91M 0.38M 1.26M 2.34M
Inventory 0.00M 0.42M -0.08M - -
Accounts payable 0.51M 1.23M 1.24M 4.75M 6.61M
Accumulated other comprehensive income 356.59M 339.86M 331.73M 269.36M 267.73M
Non currrent assets other 0.03M 0.10M 2.94M 3.72M 6.24M
Non current assets total 0.80M 3.41M 5.16M 4.89M 45.65M
Capital lease obligations 0.00M - - 0.26M 2.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - 7.20M -0.13M
Change to liabilities - - - -4.32M 2.96M
Total cashflows from investing activities 3.01M - - 7.20M -0.13M
Net borrowings - - - -0.90M -1.14M
Total cash from financing activities 1.39M 2.98M 9.36M 3.24M 39.52M
Change to operating activities - - - -4.01M 1.41M
Net income 0.83M -5.82M -8.45M -40.94M -26.51M
Change in cash -2.49M - -5.44M -17.57M 12.78M
Begin period cash flow 4.20M 7.00M 12.45M 30.02M 17.23M
End period cash flow 1.71M 4.20M 7.00M 12.45M 30.02M
Total cash from operating activities -6.90M -5.68M -15.20M -28.01M -26.64M
Issuance of capital stock 0.96M - - - 36.57M
Depreciation 0.17M 0.45M 0.79M 1.44M 1.52M
Other cashflows from investing activities - - 1.34M 0.23M 0.27M
Change to inventory 0.07M -0.42M - -0.31M -
Change to account receivables - - -1.21M 0.31M -1.56M
Sale purchase of stock - - - -0.12M -
Other cashflows from financing activities 0.43M 2.98M 9.50M 4.14M 40.66M
Change to netincome - - - 15.50M -3.06M
Capital expenditures 0.00M 0.12M 0.90M 0.12M 0.39M
Change in working capital -1.47M -0.18M -1.21M -4.01M 1.41M
Stock based compensation 0.12M - 0.94M 1.62M 2.17M
Other non cash items -6.43M -0.13M -7.28M 13.88M -4.70M
Free cash flow -6.90M -5.68M -16.10M -28.13M -27.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CLYYF
Celyad Oncology SA
-
-%
0.28 17.50 - 790.54 5.46 609.28 12.00
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Celyad Oncology SA

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Axis Business Park, Mont-Saint-Guibert, Belgium, 1435

32 1 039 41 00

4

Name Title Year Born
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME Co-Founder, CFO, Interim CEO & Director 1956
Mr. David Georges VP of Fin. & Admin. NA
Sara Zelkovic Communications & Investor Relations Director NA
Mr. Philippe Nobels Chief HR Officer & VP of HR 1966
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. Chief Medical Officer 1965
Ms. An Phan Head of Legal NA
Mr. Hannes Iserentant Head of Intellectual Property NA
Dr. Frédéric Lehmann VP of Clinical Devel. & Medical Affairs 1964
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME Co-Founder & Executive Director 1956
Mr. Matthew R. Kane Chief Executive Officer 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…